Sendero Wealth Management LLC Boosts Stock Holdings in Danaher Corporation $DHR

Sendero Wealth Management LLC raised its position in shares of Danaher Corporation (NYSE:DHR) by 84.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,439 shares of the conglomerate’s stock after purchasing an additional 3,395 shares during the period. Sendero Wealth Management LLC’s holdings in Danaher were worth $1,475,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. Northwest & Ethical Investments L.P. lifted its holdings in Danaher by 42.0% during the first quarter. Northwest & Ethical Investments L.P. now owns 5,140 shares of the conglomerate’s stock valued at $1,054,000 after purchasing an additional 1,520 shares during the last quarter. Quantbot Technologies LP raised its position in shares of Danaher by 51.5% in the first quarter. Quantbot Technologies LP now owns 18,799 shares of the conglomerate’s stock valued at $3,854,000 after purchasing an additional 6,389 shares during the period. Colonial Trust Advisors lifted its stake in shares of Danaher by 200.4% during the 1st quarter. Colonial Trust Advisors now owns 784 shares of the conglomerate’s stock valued at $161,000 after buying an additional 523 shares in the last quarter. Berkshire Asset Management LLC PA boosted its holdings in Danaher by 130.4% in the 1st quarter. Berkshire Asset Management LLC PA now owns 2,995 shares of the conglomerate’s stock worth $584,000 after buying an additional 1,695 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Danaher by 51.1% in the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 46,116 shares of the conglomerate’s stock valued at $9,416,000 after buying an additional 15,600 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Danaher stock opened at $222.91 on Thursday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market cap of $157.45 billion, a P/E ratio of 45.96, a price-to-earnings-growth ratio of 4.36 and a beta of 0.89. The firm’s fifty day moving average price is $219.53 and its 200-day moving average price is $206.53.

Danaher (NYSE:DHR) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the business earned $1.71 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. HSBC increased their target price on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. JPMorgan Chase & Co. increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Wells Fargo & Company lifted their target price on Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a report on Monday. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Finally, Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Twenty investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $248.25.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 30,248 shares of company stock valued at $6,609,663. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.